These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27756880)

  • 21. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
    Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
    Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer.
    Yoshida Y; Murayama T; Sato Y; Suzuki Y; Saito H; Nomura Y
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):507-14. PubMed ID: 26366891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
    Liu H; Wu Y; Zhu S; Liang W; Wang Z; Wang Y; Lv T; Yao Y; Yuan D; Song Y
    Cancer Lett; 2015 Apr; 359(2):218-25. PubMed ID: 25617799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
    Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 30. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
    Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
    Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
    Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
    Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.
    Lin SY; Chang HH; Lai YH; Lin CH; Chen MH; Chang GC; Tsai MF; Chen JJ
    PLoS One; 2015; 10(5):e0123305. PubMed ID: 25955608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Kelley MJ; Jha G; Shoemaker D; Herndon JE; Gu L; Barry WT; Crawford J; Ready N
    Cancer Invest; 2017 Jan; 35(1):32-35. PubMed ID: 27911119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.
    Choi YL; Bocanegra M; Kwon MJ; Shin YK; Nam SJ; Yang JH; Kao J; Godwin AK; Pollack JR
    Cancer Res; 2010 Mar; 70(6):2296-306. PubMed ID: 20215510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
    Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
    Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.